Gene therapy for malignant glioma

Area of Science:

• Neuro-oncology
• Molecular Biology
• Biotechnology

Background:

• Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with poor prognosis despite standard treatments.
• Recurrence and invasiveness are linked to glioma stem cell resistance, necessitating novel therapeutic strategies.
• Gene therapy presents a potential alternative by targeting genetic alterations in cancer cells.

Purpose of the Study:

• To review current gene therapy approaches for glioblastoma multiforme (GBM).
• To discuss the principles, mechanisms, advantages, and disadvantages of various gene therapy strategies.
• To highlight preclinical and clinical findings on gene therapy for GBM.

Main Methods:

• Review of preclinical and clinical studies on gene therapy for GBM.
• Analysis of different gene therapy modalities including prodrug/suicide, oncolytic, cytokine-mediated, and tumor suppressor gene therapy.
• Evaluation of viral vector improvements and combination treatment strategies.

Main Results:

• Gene therapy has shown anti-tumor efficacy in preclinical GBM studies.
• Clinical studies indicate promising safety profiles for gene therapy in GBM patients.
• Ongoing research focuses on improving transduction efficiency, viral delivery, and overall treatment efficacy.

Conclusions:

• Gene therapy is a developing field with significant potential for treating glioblastoma multiforme.
• Addressing challenges in delivery and efficacy is crucial for clinical translation.
• Further research into optimized gene therapy strategies, alone or in combination, is warranted for GBM treatment.